Shukra Pharmaceuticals Ltd.
Snapshot View

158.00 +0.60 ▲0.4%

25 November 2022, 04:01:00 PM
Volume: 386

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.shukrapharmaceuticals.com
Market Cap 24.74 Cr.
Enterprise Value(EV) 26.47 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 7.01 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 22.55 Trailing Twelve Months Ending 2022-09
Industry PE 35.02 Trailing Twelve Months Ending 2022-09
Book Value / Share 107.01 Trailing Twelve Months Ending 2022-09
Price to Book Value 1.48 Calculated using Price: 158.00
Dividend Yield 0.32 Period Ending 2022-03
No. of Shares Subscribed 0.16 Cr. 1,565,675 Shares
FaceValue 10
Company Profile
The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.38%
1 Week
-5.95%
1 Month
-23.19%
3 Month
-22.13%
6 Month
+179.40%
1 Year
+149.21%
2 Year
+273.96%
5 Year
+264.06%
10 Year
+7459.81%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -11.39 0.94 0.85 3.51 3.55 3.04 0.23 1.21 4.70
Return on Capital Employed (%) -5.78 1.83 2.40 7.41 5.94 3.62 0.77 0.54 5.79
Return on Assets (%) -4.80 0.72 0.67 2.78 2.44 1.76 0.11 0.54 2.12

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 14 14 14 15 15 15 15 16 16 17
Non Curr. Liab. 2 3 2 3 6 9 11 13 6 5
Curr. Liab. 2 1 1 2 3 4 7 7 12 10
Minority Int.
Equity & Liab. 18 18 17 19 24 28 34 36 35 31
Non Curr. Assets 11 11 11 12 16 17 19 20 19 20
Curr. Assets 7 7 6 7 8 11 14 16 16 11
Misc. Exp. not W/O
Total Assets 18 18 17 19 24 28 34 36 35 31

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 4 3 5 5 5 6 12 11 20 22
Other Income 0 1 0 0 0 0 0 0 0 0
Total Income 5 4 5 5 5 6 12 12 21 22
Total Expenditure -5 -3 -4 -4 -4 -4 -10 -10 -18 -19
PBIDT 0 1 1 2 2 2 2 2 3 4
Interest 0 0 0 0 0 0
Depreciation -1 -1 0 0 -1 -1 -1 -1 -2 -2
Taxation 0 0 0 -1 0 0 0 0 0 0
Exceptional Items 0 -1 0 0
PAT -1 0 0 1 1 0 0 0 1 1
Adjusted EPS -5 1 1 3 3 3 0 1 5 7

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 10 -3 -2 3 0 1 0 1 1 8
Cash Fr. Inv. -11 2 1 0 -1 -5 -2 -3 -2 -2
Cash Fr. Finan. 1 2 1 -1 3 2 2 2 -7
Net Change 0 0 0 1 -1 0 0 0 0 0
Cash & Cash Eqvt 0 1 1 2 1 0 0 0 1 0

Shareholding Pattern View Details >>

9 Qtrs 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 49.17 49.17 49.17 49.17 49.17 49.17 49.17 49.17 49.17
Public 50.83 50.83 50.83 50.83 50.83 50.83 50.83 50.83 50.83
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 12 Nov 2022
Outcome For Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2022
1. Considered adopted and approved Unaudited Financial Results for the quarter and half year ended on 30th September 2022 along with the Limited Review Report thereon. 2. Reconstitution of the Committees of the Company.3. Reviewed business of the company.
Sat, 12 Nov 2022
Board Meeting Outcome for Outcome Of Meeting Of Board Of Director Held On 12Th November 2022
1. Considered adopted and approved Unaudited Financial Results for the quarter and half year ended on 30th September 2022 along with the Limited Review Report thereon. 2. Reconstitution of the following Committees of the Company:3. Reviewed business of the company.
Thu, 03 Nov 2022
Board Meeting Intimation for Considering And Approving Unaudited Financial Results For The Quarter And Half Year Ended 30Th On September 2022
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve Notice is hereby given that the pursuant to the Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Meeting of the Board of Directors of the Company will be held on 12th November 2022 at 03:00 p.m.

Technical Scans View Details >>

Fri, 25 Nov 2022
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 247,923.28 1,033.85 -0.1%
Cipla Ltd. 89,193.72 1,105.35 +0.9%
Divi's Laboratories Ltd. 88,708.98 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. 73,559.75 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. 68,713.97 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. 55,107.38 1,628.25 +0.8%
Abbott India Ltd. 43,050.55 20,267.50 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.40 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-09 34.75 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 29.59 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 23.60 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 82.06 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 69.14 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-09 48.82 20,267.50 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.67 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-09 4.07 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 7.30 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.53 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 11.51 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 9.05 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-09 15.86 20,267.50 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 0.04 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 0.00 20,267.50 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 13.10 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 29.95 20,267.50 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 13.10 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 29.95 20,267.50 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,267.50 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,033.85 -0.1%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,105.35 +0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,342.65 +1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,418.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,789.45 -0.5%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,628.25 +0.8%
Abbott India Ltd. Standalone 2022-03 798.70 20,267.50 +0.4%

FAQ's On Shukra Pharmaceuticals Ltd.

What is Shukra Pharma share price?

Can I buy Shukra Pharma shares now?

What is the Dividend Yield of Shukra Pharma?

What is the Market Cap of Shukra Pharma?

What are the key metrics to analyse Shukra Pharma?

What is the 52 Week High and Low of Shukra Pharma?

What is the trend of Shukra Pharma share price?